FINANCIAL DISTRICT — A company dedicated to treating prostate cancer is moving into One World Trade Center, becoming the soaring tower's first biotech tenant, the Durst Organization and Port Authority announced Wednesday.
Progenics Pharmaceuticals, Inc., a business that develops technologies, diagnostic tools and therapies related to prostate cancer, has signed a lease for a 26,500-square-foot space in the building.
"One World Trade Center's tenant roster is emblematic of the growing diversity of businesses that now call Lower Manhattan home," said Beth Wolfowitz, Port Authority director of leasing and management for the World Trade Center, in a statement.
"Once heavily dominated by a financial services center that typically closed its doors at nightfall, Lower Manhattan has been rapidly reinventing itself as a live-work-play community with employers representing a spectrum of business categories."
One WTC is now home to 25 different companies, with major tenants including media giant Conde Nast, which takes up more than 1 million square feet of office space.
The 1,776-foot-tall building opened for business in November 2014 and is currently 66 percent leased.
